Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh

Promotor: M. Danhof Co-promotor: O.E. Della Pasqua

Nuclear Magnetic Resonance (NMR) Spectroscopy is a non-destructive analytical technique that is used to study the nature and characteristics of molecules with an atomic level precision. It has a wide range of applications especially in synthetic chemistry, biological and biochemical research groups…

Developing new drugs is a difficult process. With the aid of artificial intelligence, Pharmaceutical scientist Xuhan Liu has developed methods that can help make drug design cheaper and faster. PhD defence on 15 February.

Media in the Netherlands and abroad reported extensively about the drug research led by Leiden chemist Mario van der Stelt. In this research, Van der Stelt shows which unwanted side-effects a French drug candidate has.

Development of Natural Resource for New Medicines

Leiden chemists have developed a new technique with which they can determine the role of kinases – a group of proteins – in a living cell. This technique makes it easier to find new drug targets for diseases such as cancer and rheumatoid arthritis. The team published the findings in the journal Nature…

Professor of Clinical Pharmacology Adam Cohen from Leiden University received the prestigious Dr. Saal van Zwanenberg Honorary Prize on 12 November. The prize honours a scientist who has distinguished themselves in the field of research that has directly or indirectly led to the development of new medicines…

Fascinated by science since high school, Alireza Mashaghi Tabari is driven to explore new ways of thinking in medicine. With a strong academic network, he educates students and gives public lectures. For his research at LACDR, he won the C.J. Kok Public Award 2018, making him the Faculty of Science's…

The zebrafish is a promising vertebrate model organism in early drug discovery and development.

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

Professor Thomas Hankemeier and his international research team HYPERMARKER have received a 10m-euro grant from Horizon Europe and UK Research and Innovation.

Embryonic stem cells have the remarkable ability to develop into any type of cell. On their way to become for example a liver or a heart cell, they must repeatedly decide between alternative developmental paths. How they make these decisions is largely unknown. An international team of biophysicists…

How can we prevent drug-induced liver and kidney damage? PhD candidates Marije Niemeijer and Lukas Wijaya investigated what happens in the cells during the onset of this damage: a stress response. Both focused on a different subtopic and made some interesting discoveries.

There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

According to the LUMC, patients experience 30% fewer serious side effects when medication doses are tailored to their DNA.

Not taking into account the saturation of drug targets can lead to wrong conclusions about the duration of a drug's action. This is what former PhD candidate Wilbert de Witte writes together with the Leiden professors of pharmacology Meindert Danhof, Piet van der Graaf, and Liesbeth de Lange in Nature…

Leiden University and Leiden University Medical Center have joined the Netherlands Centre for One Health (NCOH), further strengthening the academic network in which such problems as antimicrobial resistance are studied.

Researchers at Leiden University have made a breakthrough in the study of the hereditary Pompe disease. Together with colleagues in York, they have developed a molecule that binds to the enzyme that is key to the progress of the disease. The findings have been published in ACS Central Science.

It sounds futuristic, but it is possible: the creation of miniature organs of patients in order to study them and see how diseases develop and can be treated. This is what researchers from the LUMC, Twente University (UT), UMCG, TU Delft and the Hubrecht Institute hope to achieve in the next ten years…

Before patients can take a pill, scientists often spend years in the lab developing and testing a candidate drug. That often includes experiments with laboratory animals. As head of the rodent facility, Ilze Bot and her colleagues ensure that these experiments are conducted in an ethically responsible…

Pharma company Janssen has begun construction on a new office and lab building at the Leiden Bio Science Park. The first pile of the 13,500 square metre building has been driven into the ground.

Edith Schippers, Minister of Health, will be investing six million euros over the coming four years to boost research on new antibiotics. The programme will be set up by several different parties, including the Leiden Centre for Antimicrobial Research.

Public funding for fundamental research is essential for innovation and the development of new medicines. This is demonstrated by Professor Science Based Business Simcha Jong and his colleague Hsini Huang after studying US federal funding restrictions for stem cell research under President George W.…

Medicines do not follow the one size fits all principle, because genetic differences can influence their efficiency. That is what research by PhD candidate Julia Hillger shows. She defends her PhD dissertation Take it Personal on Thursday 7 December.

The Clinical Epidemiology department at the LUMC has set up a series of lectures for asylum seekers. The series has become a huge success.